Two experimental Ebola treatments — Regeneron's REGN-EB3 and another antibody-based therapy called mAb114 — are advancing to an extension phase of a large clinical trial after an it was determined they offer significantly better survival rates than the standard of care. Yourway is pleased with this clinical progress, having assisted Regeneron in rapidly delivering experimental Ebola drugs to infected patients in the Congo during the 2018 outbreak.